Global Rank
#23327
Country Rank
#68
Market Cap
116.41 M
Price
0.34
Change (%)
0.97%
Volume
540,280
Aroa Biosurgery Limited's latest marketcap:
116.41 M
As of 06/07/2025, Aroa Biosurgery Limited's market capitalization has reached $116.41 M. According to our data, Aroa Biosurgery Limited is the 23327th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 116.41 M |
| Revenue (ttm) | 49.96 M |
| Net Income (ttm) | -2,249,047.77 |
| Shares Out | 344.9 M |
| EPS (ttm) | -0.01 |
| Forward PE | 60.50 |
| Ex-Dividend Date | n/a |
| Earnings Date | 06/30/2025 |
Market Cap Chart
Data Updated: 06/07/2025
Aroa Biosurgery Limited's yearly market capitalization.
Aroa Biosurgery Limited has seen its market value drop from A$345.84 M to A$179.35 M since 2020, representing a total decrease of 48.14% and an annual compound decline rate (CAGR) of 13.76%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/07/2025 | A$179.35 M | -32.47% |
| 12/31/2024 | A$265.57 M | -6.83% |
| 12/29/2023 | A$285.06 M | -23.02% |
| 12/30/2022 | A$370.32 M | 6.07% |
| 12/31/2021 | A$349.14 M | 0.96% |
| 12/31/2020 | A$345.84 M |
Company Profile
Aroa Biosurgery Limited Overview
Aroa Biosurgery Limited specializes in the development, manufacturing, and sale of medical devices for wound and soft tissue repair. The company leverages extracellular matrix (ECM) technology and operates in the United States and internationally.
Key Products
- Endoform Natural & Antimicrobial Restorative Bioscaffold – Designed for acute and chronic wound treatment.
- Myriad Matrix – Engineered ECM for soft tissue repair, reinforcement, and complex wounds.
- Myriad Morcells – A powdered ECM format for soft tissue repair and complex wounds.
- Myriad Morcells Fine – Delivers ECM proteins to initiate and sustain healing.
- OviTex & OviTex PRS – Reinforced bioscaffolds for hernia repair, abdominal wall reconstruction, and breast reconstruction.
- Symphony – A cellular and tissue product for regenerating functional tissue in complex wounds.
Company Background
Aroa Biosurgery Limited was founded in 2007 and is headquartered in Auckland, New Zealand.
Frequently Asked Questions
-
What is Aroa Biosurgery Limited's (ASX-ARX) current market cap?As of 06/07/2025, Aroa Biosurgery Limited (including the parent company, if applicable) has an estimated market capitalization of $116.41 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Aroa Biosurgery Limited (ASX-ARX) rank globally by market cap?Aroa Biosurgery Limited global market capitalization ranking is approximately 23327 as of 06/07/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.